162 related articles for article (PubMed ID: 22147873)
1. An MS patient loses trust when she finds out her doctor is paid by drug companies.
Wolston M
Health Aff (Millwood); 2011 Dec; 30(12):2449-52. PubMed ID: 22147873
[No Abstract] [Full Text] [Related]
2. Physicians with conflicts of interest.
Silver-Isenstadt J
Health Aff (Millwood); 2012 Apr; 31(4):885; author reply 885. PubMed ID: 22492909
[No Abstract] [Full Text] [Related]
3. Trusting one's physician.
Glazer WM
Health Aff (Millwood); 2012 Apr; 31(4):884; author reply 885. PubMed ID: 22492907
[No Abstract] [Full Text] [Related]
4. Letting the sunshine in on doctor-pharma relationships.
Jack A
BMJ; 2011 Oct; 343():d6459. PubMed ID: 21990283
[No Abstract] [Full Text] [Related]
5. Sunlight as disinfectant--new rules on disclosure of industry payments to physicians.
Rosenthal MB; Mello MM
N Engl J Med; 2013 May; 368(22):2052-4. PubMed ID: 23718162
[No Abstract] [Full Text] [Related]
6. "Transparency reports" on industry payments to physicians and teaching hospitals.
Steinbrook R; Ross JS
JAMA; 2012 Mar; 307(10):1029-30. PubMed ID: 22336624
[No Abstract] [Full Text] [Related]
7. Doctors and drug companies--scrutinizing influential relationships.
Campbell EG
N Engl J Med; 2007 Nov; 357(18):1796-7. PubMed ID: 17978288
[No Abstract] [Full Text] [Related]
8. Shedding light on what the Sunshine Act will mean for physicians.
Katayama AC
WMJ; 2012 Feb; 111(1):39-40. PubMed ID: 22533215
[No Abstract] [Full Text] [Related]
9. Doctors and drug companies.
Blumenthal D
N Engl J Med; 2004 Oct; 351(18):1885-90. PubMed ID: 15509823
[No Abstract] [Full Text] [Related]
10. Shining a light on the Sunshine Act.
Peck AA
J Med Assoc Ga; 2013; 102(2):28. PubMed ID: 24006732
[No Abstract] [Full Text] [Related]
11. Managing physician financial conflicts of interest in clinical trials conducted in the private practice setting.
Williams KM
Food Drug Law J; 2004; 59(1):45-77. PubMed ID: 15190925
[No Abstract] [Full Text] [Related]
12. Already feeling the heat: Docs rethinking payments as Sunshine Act looms.
Lee J
Mod Healthc; 2013 Jul; 43(26):12-3. PubMed ID: 23878901
[No Abstract] [Full Text] [Related]
13. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no.
Hillert J
Mult Scler; 2013 Jan; 19(1):26-8. PubMed ID: 23303881
[No Abstract] [Full Text] [Related]
14. Transparency urged over research payments.
Check E
Nature; 2007 Aug; 448(7155):738. PubMed ID: 17700667
[No Abstract] [Full Text] [Related]
15. Let the Sun Shine In! An Adventure in Open Payments.
Barry MJ
Ann Intern Med; 2018 Jan; 168(2):151-152. PubMed ID: 29335735
[No Abstract] [Full Text] [Related]
16. Disclosure UK: transparency should no longer be an optional extra.
Adlington K; Godlee F
BMJ; 2016 Jul; 354():i3730. PubMed ID: 27383187
[No Abstract] [Full Text] [Related]
17. Medical students protest perks from drug companies.
Opar A
Nat Med; 2006 Oct; 12(10):1104. PubMed ID: 17024192
[No Abstract] [Full Text] [Related]
18. Natalizumab: infections, hypersensitivity, etc.
Prescrire Int; 2011 Dec; 20(122):297. PubMed ID: 22232812
[No Abstract] [Full Text] [Related]
19. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust.
Klein E; Solomon AJ; Corboy J; Bernat J
Mult Scler Relat Disord; 2016 Jul; 8():4-8. PubMed ID: 27456867
[TBL] [Abstract][Full Text] [Related]
20. Disclosure UK website gives "illusion of transparency," says Goldacre.
Kmietowicz Z
BMJ; 2016 Jul; 354():i3760. PubMed ID: 27384062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
